
Bayer Shares U.S. Regulatory Update on Elinzanetant
Bayer Receives FDA Review Extension for Elinzanetant New Drug Application in the U.S. Bayer has announced an important regulatory update concerning its investigational drug elinzanetant, a first-in-class dual neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist developed for the…










